Results 21 to 30 of about 232,449 (132)

P53-MDM2 PATHWAY: EVIDENCES FOR A NEW TARGETED THERAPEUTIC APPROACH IN B-ACUTE LYMPHOBLASTIC LEUKEMIA

Frontiers in Pharmacology, 2016
The tumor suppressor p53 is a canonical regulator of different biological functions, like apoptosis, cell cycle arrest, DNA repair and genomic stability.
Stefania Trino, Luciana De Luca, Ilaria Laurenzana, Antonella Caivano, Luigi Del Vecchio, Luigi Del Vecchio, Giovanni Martinelli, Pellegrino Musto   +7 more
doaj   +1 more source

GSTT1null and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients

Frontiers in Oncology, 2021
IntroductionGlutathione S-transferase (GST) gene deletion or polymorphic sequence variations lead to decreased enzyme activity that influences susceptibility and response to chemotherapy in acute lymphoblastic leukemia (ALL).
Shahid M. Baba, Arshad A. Pandith, Zafar A. Shah, Sajad A. Geelani, Javid R. Bhat, Ayaz Gul, Sameer A. Guru, Hamed A. El-Serehy, Abid M. Koul, Sheikh Mansoor   +9 more
doaj   +1 more source

IMMUNOPHENOTYPIC COMPARISON BETWEEN REACTIVE BONE MARROW B-LYMPHOCYTE PRECURSOR (HEMATOGONES) AND B-NEOPLASTIC LYMPHOBLAST LEUKAEMIA USING CD 34, CD 123 BY FLOWCYTOMETRY

The Iraqi Journal of Medical Sciences, 2016
Background:Flow cytometric study found that lymphoblasts of B acute lymphoblastic leukemia exhibited multiple aberrant antigens by which they can be distinguished from hematogones. These antigens are CD34 and CD123.
Yousra A. Shallan, Raad J. Musa
doaj   +4 more sources

Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia

Haematologica
Immunotherapy has revolutionized treatment for a wide variety of cancers yet its use has been relatively limited in childhood malignancies. With the introduction of bispecific T-cell engagers (BiTE®) and chimeric antigen T-cell receptor technologies ...
Kaylyn Utley Lyons, Lia Gore
doaj   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia [PDF]

, 2013
Purpose: Aberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase ...
Oliver G Ottmann, Martin Ruthardt, Oliver G. Ottmann, Oliver G. Ottmann (485229), Falkenburg, J.H.F., Marcus Liebermann (485228), Bart A. Nijmeijer (485227), Pfeifer, Heike, Falkenburg, J. H. Frederik, J. H. Frederik Falkenburg, Ruthardt, Martin, Tamara Tesanovic, Tesanovic, Tamara, Bart A Nijmeijer, Heike Pfeifer, Ottmann, Oliver G., Susanne Badura (485223), Sylvia Wystub, Sylvia Wystub (485226), Liebermann, M., Marcus Liebermann, Bart A. Nijmeijer, Ottmann, O.G., Nijmeijer, Bart A., Badura, S., Susanne Badura, Wystub, Sylvia, Pfeifer, H., J H Frederik Falkenburg, Tamara Tesanovic (485224), Martin Ruthardt (66634), Wystub, S., Nijmeijer, B.A., Ruthardt, M., Tesanovic, T., Badura, Susanne, Heike Pfeifer (485225), J. H. Frederik Falkenburg (210432), Liebermann, Marcus   +38 more
core   +1 more source

Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia

Frontiers in Oncology, 2022
Measuring minimal residual disease (MRD) during treatment is valuable to identify acute lymphoblastic leukemia (ALL) patients who require intensified treatment to avert relapse. We performed the next-generation sequencing (NGS)-based immunoglobulin gene (
Jae Wook Lee, Jae Wook Lee, Yonggoo Kim, Yonggoo Kim, Ari Ahn, Jong Mi Lee, Jong Mi Lee, Jae Won Yoo, Jae Won Yoo, Seongkoo Kim, Seongkoo Kim, Bin Cho, Bin Cho, Nack-Gyun Chung, Nack-Gyun Chung, Myungshin Kim, Myungshin Kim   +16 more
doaj   +1 more source

p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia [PDF]

, 2011
Background: The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome.
Mahajna, Jamal, Y. Najajreh, Ruthardt, Martin, M. Ruthardt, Ottmann, Oliver G., J. Mahajna, Mian, Afsar Ali, Mian, Afsar A., Metodieva, Anna, Najajreh, Yousef, A. Metodieva, A. A. Mian, O. G. Ottmann   +12 more
core   +1 more source

Secondary B-acute lymphoblastic leukemia following lenalidomide maintenance in multiple myeloma

Indian Journal of Pathology and Microbiology
Following the advent of immunomodulatory agents (IMiDs) in the treatment of multiple myeloma (MM), the progression-free survival has improved significantly.
Raghuveer S. Prabhu, R Pranav, Jay Mehta
doaj   +1 more source

Preserved cellular immunity in smoldering acute leukemia [PDF]

, 1976
"Smoldering acute leukemia", a variant of acute myelogenous leukemia, has been recognized with frequent incidence in recent years. This is chracterized by benign clinical course, poor physical findings, leukopenia and mild anemia in the ...
Hironobu Toki, Toki, Hironobu
core   +1 more source

Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification

Discover Oncology, 2022
Purpose Although risk-stratified chemotherapy regimens improve B-cell acute lymphoblastic leukemia (B-ALL) clinical outcome, relapse occurs in a significant number of cases.
Vitória Brum da Silva Nunes, Camila Kehl Dias, Juliete Nathali Scholl, Alexia Nedel Sant’Ana, Amanda de Fraga Dias, Mariela Granero Farias, Ana Paula Alegretti, Monalisa Sosnoski, Liane Esteves Daudt, Mariana Bohns Michalowski, Ana Maria Oliveira Battastini, Alessandra Aparecida Paz, Fabrício Figueiró   +12 more
doaj   +1 more source